NOT MEDICAL ADVICE

TB-500

Estimated Market Price
$94.99 $109.99
Based on verified supplier pricing for research-grade compounds
Thymosin Beta-4 for recovery, flexibility, and tissue repair. Ideal for joint health and injury support. Lab tested.
How it works

Regulates a key structural protein inside cells to boost their ability to move and migrate to injury sites. This speeds up wound healing and reduces inflammation.

Joint Health

Performance

Recovery & Longevity

bestseller

What to Expect
Days 1–3 Initial inflammatory modulation begins at cellular level. Subtle - most people feel nothing yet.
Week 1–2 Reduced swelling and improved range of motion observed. Swelling goes down; joints feel less stiff in the morning.
Week 3–4 Enhanced cell migration accelerates wound-healing cascades. Wounds heal faster; range of motion noticeably better.
Week 5–6 Significant tissue remodeling; reduced scar formation noted. Old scars feel softer; chronic tightness loosening up.
Week 7–8 Full repair cycle completing; reassess protocol continuation. Injuries feel well-repaired; flexibility much improved.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 250–500 mcg/day SC
Administration Subcutaneous injection
Schedule Once daily, AM on empty stomach
Protocol Duration 4–8 weeks
Half-Life Not well established
Side Effects & Safety
Tolerability Profile Mild

Generally well tolerated; side effects are mild and transient

Common Side Effects

  • Injection site swelling or rednessmost users
  • Mild fatigue day of injectionsome users

Less Common

  • Headacheoccasional
  • Localized skin reactionoccasional
  • Low-grade fever (immune response)occasional
  • Nauseaoccasional

Discontinue If

  • Severe allergic reaction (rash, swelling, difficulty breathing)
  • Persistent fever above 38.5°C / 101.3°F
  • Unusual bleeding or bruising

Contraindications

  • Pregnancy or breastfeeding
  • Active cancer or tumors (promotes cell migration)
  • Known hypersensitivity to thymosin beta-4

Data note: Preclinical safety profile is favorable. Human trial data is limited to Phase I/II wound healing studies.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about TB-500
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for TB-500

Also Known As Thymosin Beta-4, Tβ4, TB4
Classification Actin-sequestering protein · Tissue Repair
Sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 aa)
Molecular Formula C₂₁₂H₃₅₀N₅₆O₇₈S
Molecular Weight 4,963.50 Da
CAS Number 77591-33-4
Half-Life Not well established
Origin Thymus gland - most abundant intracellular peptide
Administration Subcutaneous injection
Status Research · Phase I/II clinical trials for wound healing
Mechanism of Action Regulates a key structural protein inside cells to boost their ability to move and migrate to injury sites. This speeds up wound healing and reduces inflammation.
Research Overview Thymosin Beta-4 (TB-500) is a 43-amino-acid peptide that holds the distinction of being the most abundant intracellular peptide found in mammalian cells, present in virtually all tissue types except red blood cells. First isolated from calf thymus tissue by Allan Goldstein and colleagues at the George Washington University in the 1960s as part of the thymosin fraction 5 complex, TB-500 was initially believed to function primarily in immune regulation. However, subsequent research revealed its central role as a major actin-sequestering molecule, binding monomeric G-actin to regulate the polymerization and depolymerization dynamics of the cellular cytoskeleton. This fundamental function in cytoskeletal organization underpins TB-500's remarkable effects on cell migration, a process critical to wound healing and tissue repair. When tissue damage occurs, TB-500 is released from platelets and other cells at the injury site, establishing a chemotactic gradient that directs the migration of endothelial cells, keratinocytes, and progenitor cells toward the wound. Beyond its actin-related functions, TB-500 has been shown to possess potent anti-inflammatory properties, reducing the production of pro-inflammatory cytokines and chemokines while promoting the expression of anti-inflammatory mediators. In cardiac research, TB-500 has demonstrated particularly compelling results - studies in mouse models of myocardial infarction showed that systemic administration reactivated quiescent epicardial progenitor cells, promoting neovascularization and cardiomyocyte survival in the infarcted region. The peptide has also been studied extensively in dermal wound healing, corneal repair, and neurological injury models. In equine veterinary medicine, TB-500 gained early attention for its ability to accelerate recovery from tendon and ligament injuries in racehorses, though its use was subsequently banned by most racing authorities. Clinical translation has been slower than preclinical promise would suggest, with a Phase II trial by RegeneRx Biopharmaceuticals for chronic and acute wounds showing positive but inconclusive results.

Citations

Published findings on TB-500 from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.